Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPEDITION long-term follow-up after delandistrogene moxeparvovec
jRCT2053240056Phase 3Not yet recruiting
- Sponsor
- Sarepta Therapeutics
- Start
- Aug 2024
- Modality
- Gene Therapies
01
Overview
Phase 3, open-label, single-arm trial of delandistrogene moxeparvovec in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Primary endpoint: Treatment-emergent adverse events. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
delandistrogene moxeparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT2053240056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053240056.